JP2013501056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501056A5 JP2013501056A5 JP2012523680A JP2012523680A JP2013501056A5 JP 2013501056 A5 JP2013501056 A5 JP 2013501056A5 JP 2012523680 A JP2012523680 A JP 2012523680A JP 2012523680 A JP2012523680 A JP 2012523680A JP 2013501056 A5 JP2013501056 A5 JP 2013501056A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- polyomavirus
- subject
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 241001505332 Polyomavirus sp. Species 0.000 claims 4
- 239000003018 immunosuppressive agent Substances 0.000 claims 4
- 206010061598 Immunodeficiency Diseases 0.000 claims 3
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000001494 anti-thymocyte effect Effects 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- -1 infliximab Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229950007856 mofetil Drugs 0.000 claims 1
- 229940014456 mycophenolate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229940079023 tysabri Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23093109P | 2009-08-03 | 2009-08-03 | |
| US61/230,931 | 2009-08-03 | ||
| PCT/US2010/044093 WO2011017253A1 (en) | 2009-08-03 | 2010-08-02 | Composition and methods of treating viral infections and viral induced tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501056A JP2013501056A (ja) | 2013-01-10 |
| JP2013501056A5 true JP2013501056A5 (enExample) | 2013-09-12 |
Family
ID=43544613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523680A Pending JP2013501056A (ja) | 2009-08-03 | 2010-08-02 | ウイルス感染およびウイルス誘発腫瘍を治療する組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120164104A1 (enExample) |
| EP (1) | EP2462152A4 (enExample) |
| JP (1) | JP2013501056A (enExample) |
| AU (1) | AU2010279678B2 (enExample) |
| BR (1) | BR112012002551A2 (enExample) |
| CA (1) | CA2770282A1 (enExample) |
| WO (1) | WO2011017253A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| US8524248B2 (en) | 2007-12-14 | 2013-09-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods to diagnose and immunize against the virus causing human Merkel cell carcinoma |
| MX2010008148A (es) | 2008-01-25 | 2010-10-20 | Chimerix Inc | Métodos de tratamiento de infecciones virales. |
| WO2009111486A2 (en) * | 2008-03-04 | 2009-09-11 | The Regents Of The University Of California | Reversing the immune decline of aging by a nutraceutical antioxidant in mice |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| CA2779473C (en) * | 2009-10-30 | 2016-08-16 | Chimerix, Inc. | Methods of treating viral associated diseases |
| WO2011100698A2 (en) | 2010-02-12 | 2011-08-18 | Chimerix, Inc. | Methods of treating viral infection |
| EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | Methods of treating retroviral infections and related dosage regimes |
| CN103209985B (zh) * | 2010-08-31 | 2016-08-24 | 奇默里克斯公司 | 膦酸酯衍生物及其合成方法 |
| EP2770834A4 (en) * | 2011-10-26 | 2015-11-25 | Chimerix Inc | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| US9593137B2 (en) | 2011-12-22 | 2017-03-14 | Geron Corporation | Guanine analogs as telomerase substrates and telomere length affectors |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| JP6462659B2 (ja) | 2013-03-15 | 2019-01-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非環式ヌクレオシドホスホン酸ジエステル |
| WO2014146218A1 (zh) * | 2013-03-22 | 2014-09-25 | 当代绿能科技股份有限公司 | 马替麦考酚酯或其盐类用于制备抗流感病毒之药物的用途 |
| WO2015073148A1 (en) * | 2013-11-15 | 2015-05-21 | Chimerix Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters |
| CN112898345A (zh) | 2014-09-15 | 2021-06-04 | 加利福尼亚大学董事会 | 核苷酸类似物 |
| US10160778B2 (en) | 2014-10-27 | 2018-12-25 | Concert Pharmaceuticals, Inc. | Pyrimidine phosphonic acid esters |
| GB201509431D0 (en) * | 2015-06-01 | 2015-07-15 | Equigerminal Sa | Antiviral composition |
| EP3350191B9 (en) | 2015-09-15 | 2021-12-22 | The Regents of the University of California | Nucleotide analogs |
| CN118416082A (zh) | 2016-06-28 | 2024-08-02 | 应急生物防御行动兰辛有限责任公司 | 布林西多福韦的制剂 |
| AU2020334152A1 (en) | 2019-08-22 | 2022-03-24 | Emory University | Nucleoside prodrugs and uses related thereto |
| CN113288896A (zh) * | 2021-05-28 | 2021-08-24 | 成都中医药大学 | 槐定碱在制备抗疱疹病毒的药物中的用途 |
| CA3262284A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences Inc | Pharmaceutical compositions and forms for the treatment of human papillomavirus (HPV) infection and HPV-induced neoplasm |
| AU2022476501A1 (en) * | 2022-08-31 | 2025-03-13 | Symbio Pharmaceuticals Limited | Pharmaceutical composition for treating lymphoma |
| JP2025065589A (ja) * | 2022-08-31 | 2025-04-22 | シンバイオ製薬株式会社 | リンパ腫の治療用医薬組成物 |
| EP4582087A4 (en) * | 2022-08-31 | 2025-09-24 | Symbio Pharmaceuticals Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LYMPHOMA |
| TW202500152A (zh) * | 2023-04-21 | 2025-01-01 | 日商新百歐醫藥有限公司 | 用於治療神經膠質瘤的藥物組合物 |
| CN119080836B (zh) * | 2024-11-07 | 2025-04-15 | 上海柯君医药科技有限公司 | 一种正痘病毒抑制剂及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA777769A (en) | 1963-03-18 | 1968-02-06 | H. Roy Clarence | Substituted methylene diphosphonic acid compounds and detergent compositions |
| DE1248654B (de) | 1964-11-11 | 1967-08-31 | Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) | Verfahren zur Herstellung von Phosphonsäuren und deren Salzen |
| DE2943498C2 (de) | 1979-10-27 | 1983-01-27 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure |
| US5047533A (en) | 1983-05-24 | 1991-09-10 | Sri International | Acyclic purine phosphonate nucleotide analogs |
| IT1196315B (it) | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
| IL77243A (en) | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| GB8530603D0 (en) | 1985-12-12 | 1986-01-22 | Leo Pharm Prod Ltd | Chemical compounds |
| DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
| CS264222B1 (en) | 1986-07-18 | 1989-06-13 | Holy Antonin | N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them |
| US5247085A (en) | 1987-11-30 | 1993-09-21 | Beecham Group P.L.C. | Antiviral purine compounds |
| SU1548182A1 (ru) | 1987-12-29 | 1990-03-07 | Институт молекулярной биологии АН СССР | 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ |
| IL91362A0 (en) | 1989-08-20 | 1990-03-19 | Yissum Res Dev Co | Bisphosphonates,process for preparing them and pharmaceutical compositions containing them |
| US5196409A (en) | 1989-08-20 | 1993-03-23 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism |
| IT1241674B (it) | 1989-10-12 | 1994-01-27 | Boehringer Biochemia Srl | Acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono. |
| US5039819A (en) | 1990-09-18 | 1991-08-13 | Merck & Co., Inc. | Diphosphonate intermediate for preparing an antihypercalcemic agent |
| FI89365C (fi) | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
| US5183815A (en) | 1991-01-22 | 1993-02-02 | Merck & Co., Inc. | Bone acting agents |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5300687A (en) | 1991-07-18 | 1994-04-05 | Ortho Pharmaceutical Corporation | Trifluoromethylbenzylphosphonates useful in treating osteoporosis |
| US5270365A (en) | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| JP3141053B2 (ja) | 1991-12-26 | 2001-03-05 | アベンティス ファーマ株式会社 | ビスホスホン酸誘導体 |
| CA2136820C (en) | 1992-05-29 | 1997-09-09 | Susan M. Kaas | Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism |
| EP0600371B1 (de) | 1992-12-02 | 1999-02-03 | Hoechst Aktiengesellschaft | Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5817647A (en) | 1993-04-01 | 1998-10-06 | Merrell Pharmaceuticals Inc. | Unsaturated acetylene phosphonate derivatives of purines |
| US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| JPH09506333A (ja) | 1993-09-17 | 1997-06-24 | ギリアード サイエンシーズ,インコーポレイテッド | 治療化合物の投薬方法 |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| EP0753523A1 (en) | 1995-07-10 | 1997-01-15 | Gador S.A. | Amino-substituted bisphosphonic acids |
| US5885973A (en) | 1995-12-27 | 1999-03-23 | Gador, S.A. | Bone mass anabolic composition comprising olpadronate |
| US5717095A (en) | 1995-12-29 | 1998-02-10 | Gilead Sciences, Inc. | Nucleotide analogs |
| TW369536B (en) | 1996-01-18 | 1999-09-11 | Mitsubishi Chem Corp | Phosphonate nucleotide compounds |
| US5877166A (en) | 1996-04-29 | 1999-03-02 | Sri International | Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5760013A (en) | 1996-08-21 | 1998-06-02 | National Science Council | Thymidylate analogs and the use thereof |
| AU8828598A (en) * | 1997-08-15 | 1999-03-08 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| DE60011637T2 (de) | 1999-09-24 | 2004-11-11 | Shire Biochem Inc., Laval | Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen |
| MXPA02005490A (es) | 1999-12-03 | 2004-09-10 | Univ California San Diego | Compuestos de fosfonato. |
| US20050187192A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| WO2007130783A2 (en) * | 2006-05-03 | 2007-11-15 | Chimerix, Inc. | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
| JP2010525063A (ja) * | 2007-04-27 | 2010-07-22 | キメリクス,インコーポレイテッド | ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 |
| WO2008150438A1 (en) * | 2007-06-01 | 2008-12-11 | Luitpold Pharmaceuticals, Inc. | Pmea lipid conjugates |
-
2010
- 2010-08-02 AU AU2010279678A patent/AU2010279678B2/en active Active
- 2010-08-02 WO PCT/US2010/044093 patent/WO2011017253A1/en not_active Ceased
- 2010-08-02 BR BR112012002551A patent/BR112012002551A2/pt not_active IP Right Cessation
- 2010-08-02 CA CA2770282A patent/CA2770282A1/en not_active Abandoned
- 2010-08-02 US US13/388,771 patent/US20120164104A1/en not_active Abandoned
- 2010-08-02 JP JP2012523680A patent/JP2013501056A/ja active Pending
- 2010-08-02 EP EP10806986A patent/EP2462152A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501056A5 (enExample) | ||
| JP6875454B2 (ja) | Hivを治療するためのトール様受容体の調節因子 | |
| JP2009528369A5 (enExample) | ||
| JP2013543501A5 (enExample) | ||
| US20100227801A1 (en) | Pharmaceutical compositions | |
| JP2017527532A5 (enExample) | ||
| JP2015506348A5 (enExample) | ||
| JP2022009683A (ja) | テノホビルアラフェナミドの結晶形態 | |
| US20170340642A1 (en) | Combinations and methods comprising a capsid assembly inhibitor | |
| JP2019515908A5 (enExample) | ||
| JP2011225596A5 (enExample) | ||
| JP2014504643A5 (enExample) | ||
| Gultekin et al. | Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach | |
| JP2010514834A5 (enExample) | ||
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| US9872895B2 (en) | TLR5 ligands, therapeutic methods, and compositions related thereto | |
| KR20180058659A (ko) | 에베롤리무스와 닥톨리십의 약제학적 병용물 | |
| CA3176642A1 (en) | Cysteamine for the treatment of sars-cov-2 infection | |
| KR20150046083A (ko) | Hcv의 거대환형 프로테아제 저해제, 비뉴클레오시드계 hcv 저해제 및 리토나비르의 조합물 | |
| WO2012061060A1 (en) | Use of teriflunomide for treating brain atrophy | |
| WO2015016694A1 (es) | Composición sólida estable de inmunosupresores | |
| JP2017514834A (ja) | Hcv感染症を治療するための組合せ療法 | |
| WO2025208047A1 (en) | Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease | |
| JP2006522060A5 (enExample) | ||
| McDevitt | Immunosuppressive agents on the horizon |